trial · primary record
Fludarabine
Refractory Non-Hodgkin Lymphoma
| Phase | Phase 1 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 36 |
| Primary completion | 2026-10-31 |
| Primary endpoint | Proportion of participants with treatment-emergent adverse events (AEs) |
| Registry ID | NCT04545762 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:31:14.839Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT04545762
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.